6 min read

AI's cure pitch hits pharma skepticism

AI's cure pitch hits pharma skepticism
Nº 01 · The Lede Hacker News Drug discovery · Computational

Drugmaker CEOs doubt Silicon Valley's AI cure promises

Drugmaker CEOs doubt Silicon Valley's AI cure promises
Fig. IHacker News · Filed 04 Nov 2026.

Drugmaker CEOs aren't buying Silicon Valley's promise that AI will cure disease, the Wall Street Journal reports, in a piece that drew discussion on Hacker News (the tech forum run by startup investor Y Combinator). The doubt comes from the executives whose companies would have to carry any AI-found molecule through trials, manufacturing and regulators. Curing disease has become one of the AI industry's headline promises for its models. But the companies that build the models are the ones making the claim, and the companies that would have to prove it in patients are the ones judging it. In the Journal's account, that second group is not yet convinced.

Read the source →

Longer AI reasoning fails at automated bioinformatics
Fig. IIbioRxiv · Filed 04 Nov 2026.
Nº 02 bioRxiv Computational biology

Longer AI reasoning fails at automated bioinformatics

Extended reasoning fails in autonomous bioinformatics, a bioRxiv preprint argues, and proposes a fix. Extended reasoning is the mode in newer AI models that works through a problem at length before answering, and it is usually expected to give better answers. The preprint looks at agents (software that runs multi-step work on its own) inside scientific sandboxes, the isolated computing environments where they write and run analysis code. If the result holds, the most expensive setting on a model is not automatically the best one for automated analysis.

Read more →
El Agente Fármaco brings an AI scientist to drug discovery
Fig. IIIarXiv · Filed 04 Nov 2026.
Nº 03 arXiv Drug discovery · Computational

El Agente Fármaco brings an AI scientist to drug discovery

El Agente Fármaco brings the AI-scientist approach to drug discovery, according to a new arXiv paper whose authors stress that the system is built to scale. An AI scientist, in the field's usage, is an agent system that carries research through several steps on its own. The name is Spanish for "the drug agent." Its claims run into the question raised by the bioinformatics preprint above: how well do agents reason when nobody is checking each step?

Read more →
Also Filed · Four Briefs from the queue
Nº 04 bioRxiv Field report

LabWeaver ties AI data analysis to laboratory knowledge

LabWeaver grounds analysis agents in laboratory knowledge, according to a bioRxiv preprint. Its authors argue that this grounding is the way to get agent-run data analysis that scientists can rely on.

Read →
Nº 05 arXiv Field report

MedPhysBench tests language models on medical physics math

MedPhysBench tests language models on medical physics calculations and on catching errors in them, in a new arXiv paper. The benchmark, a shared test, scores both getting the math right and spotting a wrong answer.

Read →
Nº 06 Anthropic Field report

Claude checks 123 libraries' code with mathematical proofs

Anthropic's Claude formally proved security properties in the compiled code of 123 open-source libraries and found bugs that had gone undetected for years. Formal verification (mathematical proof that code does what it should) has rarely been practical at this scale.

Read →
Nº 07 OpenAI Field report

OpenAI pitches ChatGPT and Codex for hardware engineering

OpenAI pitches ChatGPT and Codex, its coding agent, as tools that speed up CAD, circuit-board design and simulation work for engineers building physical things.

Read →

Reply with your discoveries. A human reads them. Forward freely.

Agentic Discovery  ·  Nº 135  ·  04 Nov 2026

Editor's Note

Pharma CEOs are unconvinced, and one preprint finds research agents do worse when they think longer.

 

Nº 01 · The Lede  —  Hacker News  —  Drug discovery · Computational

Drugmaker CEOs doubt Silicon Valley's AI cure promises

Drugmaker CEOs doubt Silicon Valley's AI cure promises

Fig. I  Hacker News · Filed 04 Nov 2026.

Drugmaker CEOs aren't buying Silicon Valley's promise that AI will cure disease, the Wall Street Journal reports, in a piece that drew discussion on Hacker News (the tech forum run by startup investor Y Combinator). The doubt comes from the executives whose companies would have to carry any AI-found molecule through trials, manufacturing and regulators. Curing disease has become one of the AI industry's headline promises for its models. But the companies that build the models are the ones making the claim, and the companies that would have to prove it in patients are the ones judging it. In the Journal's account, that second group is not yet convinced.

Read the source →

Why it matters

Pharma controls the money and the trials that take an AI-found molecule to patients. With its leaders doubtful, the cure claim will be settled by clinical results.

 

Nº 02  —  bioRxiv  —  Computational biology

Longer AI reasoning fails at automated bioinformatics

Fig. II  bioRxiv · Filed 04 Nov 2026.

Longer AI reasoning fails at automated bioinformatics

Extended reasoning fails in autonomous bioinformatics, a bioRxiv preprint argues, and proposes a fix. Extended reasoning is the mode in newer AI models that works through a problem at length before answering, and it is usually expected to give better answers. The preprint looks at agents (software that runs multi-step work on its own) inside scientific sandboxes, the isolated computing environments where they write and run analysis code. If the result holds, the most expensive setting on a model is not automatically the best one for automated analysis.

Read more →

 

Nº 03  —  arXiv  —  Drug discovery · Computational

El Agente Fármaco brings an AI scientist to drug discovery

Fig. III  arXiv · Filed 04 Nov 2026.

El Agente Fármaco brings an AI scientist to drug discovery

El Agente Fármaco brings the AI-scientist approach to drug discovery, according to a new arXiv paper whose authors stress that the system is built to scale. An AI scientist, in the field's usage, is an agent system that carries research through several steps on its own. The name is Spanish for "the drug agent." Its claims run into the question raised by the bioinformatics preprint above: how well do agents reason when nobody is checking each step?

Read more →

 

Also Filed  ·  Four Briefs from the queue

Nº 04  —  bioRxiv  —  Field report

LabWeaver ties AI data analysis to laboratory knowledge

LabWeaver grounds analysis agents in laboratory knowledge, according to a bioRxiv preprint. Its authors argue that this grounding is the way to get agent-run data analysis that scientists can rely on.

Read →

Nº 05  —  arXiv  —  Field report

MedPhysBench tests language models on medical physics math

MedPhysBench tests language models on medical physics calculations and on catching errors in them, in a new arXiv paper. The benchmark, a shared test, scores both getting the math right and spotting a wrong answer.

Read →

Nº 06  —  Anthropic  —  Field report

Claude checks 123 libraries' code with mathematical proofs

Anthropic's Claude formally proved security properties in the compiled code of 123 open-source libraries and found bugs that had gone undetected for years. Formal verification (mathematical proof that code does what it should) has rarely been practical at this scale.

Read →

Nº 07  —  OpenAI  —  Field report

OpenAI pitches ChatGPT and Codex for hardware engineering

OpenAI pitches ChatGPT and Codex, its coding agent, as tools that speed up CAD, circuit-board design and simulation work for engineers building physical things.

Read →

 

· · ·

Reply with your discoveries. A human reads them. Forward freely.